March 5, 2018 / 2:36 PM / 3 months ago

BRIEF-Magenta Therapeutics And Heidelberg Pharma Sign Agreement For Development Of Antibody Drug Conjugates

March 5 (Reuters) - Heidelberg Pharma Ag:

* MAGENTA THERAPEUTICS AND HEIDELBERG PHARMA SIGN EXCLUSIVE MULTI-TARGET RESEARCH AGREEMENT FOR THE DEVELOPMENT OF ANTIBODY DRUG CONJUGATES

* HEIDELBERG PHARMA AG - ‍MAGENTA WILL HAVE ACCESS TO CO’S AMANITIN TOXIN-LINKER PLATFORM TECHNOLOGY​

* HEIDELBERG PHARMA AG -MAGENTA HAS OPTION FOR EXCLUSIVE TARGET-SPECIFIC LICENSE FOR GLOBAL DEVELOPMENT, COMMERCIALIZATION RIGHTS TO PRODUCT CANDIDATES

* HEIDELBERG PHARMA AG - ‍CO TO RECEIVE UPFRONT TECHNOLOGY ACCESS, EXCLUSIVITY FEES, PAYMENTS FOR RESEARCH SUPPORT​

* HEIDELBERG PHARMA - TO BE ELIGIBLE TO RECEIVE OPTION FEES, DEVELOPMENT, REGULATORY,SALES-RELATED MILESTONE PAYMENTS UP TO $334 MILLION, UNDER CONDITIONS​ Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below